ArthoCare's Parallax acryllic resin
This article was originally published in Clinica
Executive Summary
AthroCare's Parallax acrylic resin with Tracers bone cement opacifer can be used for the fixation of pathological fractures in the vertebral body during vertebroplasty or kyphoplasty procedures. The FDA clearance coincides with the firm's launch of a new version of Parallax featuring a proprietary type of tantalum, which is designed to enhance the physician's ability to track the flow of bone cement under fluoroscopy. The Sunnyvale, California company plans to seek 510(k) clearance to use tantalum opacified cement in vertebroplasty or kyphoplasty procedures in the first quarter of 2005.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.